GIP and obesity disorder: Combined with the theory of GIP being an obesogenic hormone (53), these prior findings have highlighted the potential of GIP receptor antagonism, and today the development of GIP receptor antagonists has also emerged as an attractive therapeutic approach for addressing obesity and cardiovascular diseases (54, 55).